The Australian Centre for Cancer Glycomics was established at the Institute for Glycomics in May 2017. This unique national resource dedicated to cancer glycomics research, is the result of significant funding by Griffith University. The state of the art equipment and infrastructure, coupled with the brightest scientific talent in the field of cancer glycoproteomics, makes the A2CG an exciting hub of truly revolutionary research. The Institute for Glycomics and the A2CG are taking a highly integrated, systematic approach to identifying important cancer biomarkers and tumour-associated carbohydrate antigens (TACAs), underpinned by a strategic focus geared towards translational outcomes. The Institute for Glycomics has a proven track record in carbohydrate drug discovery and vaccine development coupled with substantial biochemistry, structural biology and medicinal chemistry infrastructure. This demonstrates the Institute’s capabilities in driving discoveries from the laboratory bench to the patient bedside. Our team of research scientists are dedicated to understanding how cancer glycans can sketch the blueprint for the next wave of drugs, vaccines, and diagnostics. Together with a foundation partner, who shares our vision of harnessing this unique research platform to identify new solutions to cancer, we aim to improve the future of those living with this intractable disease.

The A2CG Team As the only institute of its kind in the southern hemisphere, the Institute for Glycomics is already an epicentre of glycomics research globally and houses many world-leading carbohydrate researchers. A project with the vision and scale of the A2CG requires substantial human resource, technical knowledge and specialisation. Significant investment by Griffith University has attracted the world’s brightest scientific minds, including research teams led by Professor Nicolle Packer and Associate Professor Daniel Kolarich. By combining core expertise and infrastructure, the A2CG is a world-class platform for mapping the cancer glycome, and translating these discoveries into novel diagnostics and therapies. A Call to Industry Improving knowledge of the glycan structures present in cancer cells will lead to a better understanding of how to treat the most ‘un-treatable’ forms of cancer. A structured, 5-year program will systematically mine the cancer glycome; an undertaking that will remarkably transform the oncology landscape. The rapid advancement of analytical technology combined with the need for more efficacious cancer therapeutics, makes this an opportune moment for investment. With advanced technological infrastructure, knowledge and distinguished human resource, the A2CG seeks to attract a foundation partner aspiring to significantly enhance the prospects of cancer patients though innovative and revolutionary science.

Clinical Applications

The A2CG team’s extensive expertise in analytical glycoproteomics affords a
research program focussing on the following clinical applications

  • Diagnostic tools - Glycans as
    novel diagnostic and prognostic disease markers
  • Therapeutic potential - TACA identification and
    translation to develop monoclonal antibodies and other drug candidate technologies
  • Precision medicine - Development of specific and targeted medicines based on cancer glycan signatures
  • Advanced imaging - Micro-section glycomics from histopathological tissue slides to bridge histopathology and molecular imaging
  • Clinical analytics - Development of rapid, bedside diagnostic tools using focused glycomics and glycoproteomics